Deferoxamine in the Treatment of Hemophilic Synovitis by Inhibiting Macrophage Iron Overload

Abstract

Abstract Hemophilia frequently results in intra-articular bleeding, leading to substantial iron accumulation in the synovium, which facilitates M1 macrophage polarization and triggers synovitis. While current therapeutic approaches predominantly involve surgery, this study seeks to identify small molecule drug targets for treating hemophilic synovitis. In vitro RAW264.7 macrophages were categorized into five groups based on varying concentrations of deferoxamine: Ctrl, Fe, DFO1, DFO2, and DFO3. Rats were divided into five groups for differing doses of deferoxamine intra-articular injections: A-Ctrl, A-Fe, A-DFO1, A-DFO2, and A-DFO3. Excluding the A-Ctrl group, all other groups received injections of autologous venous blood into their knee joints. The relevant indexes were detected by experiment. In vitro experiments indicated no iron overload in the macrophages of any deferoxamine group, with morphological analyses showing no shift towards an M1 polarization phenotype. qPCR showed no significant change in iNOS expression, and Western Blot analysis confirmed no significant increase in iNOS and p-4E-BP1 proteins. ELISA results indicated stable levels of TNF-α and IL-6 in the supernatant. In animal studies, Prussian blue staining revealed a concentration-dependent reduction in iron deposition in the synovium across groups. Immunohistochemistry highlighted significantly higher F4/80 protein expression in the synovium of each treatment group compared to the A-Ctrl. With increased deferoxamine concentrations, iNOS and p-4E-BP1 protein expressions significantly declined, whereas Arg-1 expression notably increased, all in a concentration-dependent fashion. Iron overload within synovial cells may drive M1 macrophage polarization via phosphorylation regulation of 4E-BP1 in the mTORC1-p70S6K/4E-BP1 pathway, leading to joint cartilage damage.